Cellosaurus HCC4006/R (CVCL_S746)

Cell line name HCC4006/R
Synonyms HCC4006R; HCC4006/ER; HCC4006ER
Accession CVCL_S746
Resource Identification Initiative To cite this cell line use: HCC4006/R (RRID:CVCL_S746)
Comments Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
Omics: Deep exome analysis.
Sequence variations EGFR p.Leu747_Glu749del (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1269 (HCC4006)
Sex of cell Male
Age at sampling >50Y
Category Cancer cell line
Publications

PubMed=22773810; DOI=10.1073/pnas.1203530109
Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.-L., Pan Y., Wang L., de Stanchina E., Shien K., Aoe K., Toyooka S., Kiura K., Fernandez-Cuesta L., Fidias P., Yang J.C.-H., Miller V.A., Riely G.J., Kris M.G., Engelman J.A., Vnencak-Jones C.L., Dias-Santagata D., Ladanyi M., Pao W.
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Proc. Natl. Acad. Sci. U.S.A. 109:E2127-E2133(2012)

PubMed=23733853; DOI=10.1101/gr.152322.112
Jia P., Jin H., Meador C.B., Xia J., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z., Pao W.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Genome Res. 23:1434-1445(2013)

Cross-references
Polymorphism and mutation databases Cosmic; 1890457
Cosmic; 2015232